The GenomeWeb Top 40 index fell about 7% in March, tracking broader weakness across omics, diagnostics, and clinical laboratory stocks. The Nasdaq Biotech Index declined roughly 3%, while most of the 40 tracked companies posted month-over-month share price declines. Nautilus Biotechnology drove the standout move higher, rising about 60% after being added to the Top 40 following Abbott’s acquisition of Exact Sciences. Nautilus also announced its first early access customer for its Voyager single-molecule protein analysis platform, with Baylor College of Medicine professor Bing Zhang planning benchmarking work for protein isoform characterization in mass spectrometry data. Other notable moves included Sophia Genetics, which reported higher Q4 2025 revenue and issued 2026 guidance, and Fulgent Genetics, which completed acquisitions of pathology assets and StrataDx. The index review highlights how corporate events—especially acquisitions—continue to reshape biotech investor focus toward enabling technologies, platform revenue trajectories, and monetization speed.